A Pilot Study of the Safety and Preliminary Efficacy of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma

Trial Profile

A Pilot Study of the Safety and Preliminary Efficacy of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs BCT 100 (Primary)
  • Indications Leukaemia; Lymphoma
  • Focus Adverse reactions
  • Sponsors Bio-Cancer Treatment International
  • Most Recent Events

    • 13 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 21 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top